A phase I study of the HDM2 antagonist SAR405838 combined with the MEK inhibitor pimasertib in patients with advanced solid tumours.
Br J Cancer
; 120(3): 286-293, 2019 02.
Article
in En
| MEDLINE
| ID: mdl-30585255
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Spiro Compounds
/
Niacinamide
/
Proto-Oncogene Proteins c-mdm2
/
Indoles
/
Neoplasms
Language:
En
Journal:
Br J Cancer
Year:
2019
Document type:
Article
Affiliation country:
Países Bajos